Molecular docking confirmed strong binding between the active components (Dihydrochelerythrine, Oxysanguinarine, (S)-Canadine, (S)-Scoulerine, and (S)-Stylopine) and core targets (PTGS2, ESR1, HSP90AA1, CASP3, CDK2), suggesting that Chelidonii Herba may treat COPD patients through multi-target and multi-pathway mechanisms. Here, HSP90AA1 is linked to chronic obstructive pulmonary disease.